Lower methylated TFAP2B levels among progressive tumors may be partially explained by its contribution to the activation of the WNT/β-catenin signaling pathway, promoting cell proliferation and RCC progression [34,35,36]. The gene discussed is TFAP2B; the disease is renal cell carcinoma.